Understanding the Market | AKESO rises over 8% as the results of the HARMONi-6 study will be published simultaneously in The Lancet and ESMO LBA
I'm PortAI, I can summarize articles.
Akeso's stock price rose by more than 8%, with an increase of 6.97% as of the time of writing, reported at HKD 130.5, with a transaction volume of HKD 749 million. The company announced that the results of the Phase III clinical study of its dual-specific antibody new drug, Ivorocimab, will be published in 2025 in The Lancet and at the European Society for Medical Oncology (ESMO) conference, with a verbal presentation by Professor Lu Shun, showcasing its comparative results with PD-1 combined chemotherapy
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments